Chimerix

News Releases

2012

Chimerix Antiviral Compound CMX001 Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients

   

- Positive Phase 2 Study Results Presented in 'Best Abstracts' Oral Session at the 2012 BMT Tandem Meetings

Research Triangle Park, NC, February 6, 2012 – Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics,… > Read More

Chimerix Announces Presentation of Final Data from CMX001 Ph 2 Trial in Prophylaxis of CMV in Hematopoietic Stem Cell Transplant Patients

   

- Abstract Receives "BEST ABSTRACTS AWARD FOR CLINICAL RESEARCH" at 2012 BMT Tandem Meetings on February 3rd, 2012

RESEARCH TRIANGLE PARK, NC, January 25, 2012 – Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics,… > Read More

2011

Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences

   

DURHAM, NC, November 9, 2011 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences in New York City: the 8th… > Read More

Chimerix Honored with "2011 Southeast Bio Deal of the Year: Venture Capital Transaction" Award

   

DURHAM, NC, November 7, 2011 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, was presented with the "2011 SEBIO Deal of the Year: Venture Capital Transaction" award during a ceremony held at the conclusion of Southeast BIO's (SEBIO)… > Read More

Chimerix Announces Late-Breaker Presentation at 51st ICAAC Annual Meeting

   

- CMX001 shows no nephrotoxicity or myelosuppression in 183 patients treated under emergency INDs

DURHAM, NC, September 16, 2011 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that investigators will… > Read More

Chimerix Named by CED as a Top 25 2011 North Carolina Companies To Watch

   

August 8, 2011, Research Triangle Park - Chimerix has been selected by CED as one of 25 "NC Companies to Watch." CED, a private, nonprofit organization that promotes entrepreneurial efforts in North Carolina, has named 25 winners for the second annual North Carolina Companies To Watch… > Read More

Chimerix Commences Phase 2 Study of CMX001 for Prevention of AdV in Ped & Adult Hematopoietic Stem Cell Transplant Patients

   

- CMX001 Granted FDA Fast-Track Designation for Adenovirus Indication --

DURHAM, NC, JULY 13, 2011 - Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized,… > Read More

Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract

   

- BARDA Deletes 12 Million Optional Courses from SIGA Sole Source Contract Allowing Opportunity for Competitive Procurement of a Second Smallpox Antiviral

DURHAM, NC, June 27, 2011 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics,… > Read More

Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer

   

DURHAM, NC, March 28, 2011 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Timothy W. Trost has joined the company as Senior Vice President, Chief Financial Officer.

Mr. Trost brings to Chimerix more than 30… > Read More

Chimerix to Present at Two Upcoming Investor Conferences

   

DURHAM, NC, March 25, 2011 - Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences… > Read More

 1 2 3 >  Last ›